What is GW0742?
GW0742, sometimes written as GW-0742 or GW-610742, is a selective PPAR-δ agonist developed as a next-generation research compound related to GW-501516 (Cardarine).
Unlike anabolic agents or stimulants, GW0742 operates at the level of gene expression, regulating how the body uses fat and glucose at the cellular level.
In scientific studies, GW0742 is used to explore the role of peroxisome proliferator-activated receptor delta (PPAR-δ) in energy metabolism, cardiovascular health, and muscle performance.
Because of its high selectivity for PPAR-δ and improved potency compared to earlier analogues, it has become a valuable compound in metabolic and exercise physiology research.
How does GW0742 work?
PPAR-δ is a nuclear receptor found throughout the body — especially in skeletal muscle, adipose tissue, and the cardiovascular system.
When activated, it binds to DNA regions called PPAR response elements (PPREs), switching on genes involved in fatty-acid oxidation, glucose utilization, and energy efficiency.
In research models, GW0742 has been shown to:
- Increase fat oxidation in skeletal muscle
- Reduce lipid accumulation in the liver
- Improve mitochondrial efficiency
- Support endothelial function (vascular health)
- Modulate inflammatory pathways
These molecular effects are the reason GW0742 is often included in body composition and endurance research protocols, where scientists study how cells adapt to energy demands without increasing heart rate or blood pressure.
GW0742 Benefits (Research Context)
From the perspective of laboratory studies, the potential benefits of GW-0742 are linked to metabolic optimization and performance-related physiology.
1. Enhanced Fat Metabolism
Animal studies show that GW0742 can increase the rate of beta-oxidation, the process by which fatty acids are converted into usable energy.
This effect is driven by up-regulation of genes like CPT1, UCP3, and ACO, which together enhance mitochondrial function and energy turnover.
In metabolic research, this makes GW0742 an attractive compound for studying fat loss mechanisms that occur without the need for caloric restriction or stimulant-based metabolism boosters.
2. Improved Endurance and Energy Efficiency
Because PPAR-δ activation shifts fuel preference toward fatty acids instead of glucose, cells produce ATP (energy) more efficiently.
Rodent studies have shown that PPAR-δ agonists can extend running time and endurance significantly — not by stimulating the nervous system, but by altering muscle fiber metabolism.
This unique property is why GW-0742 is frequently referenced in bodybuilding and athletic research: it explores how cellular energy systems can be optimized without hormonal or stimulant pathways.
3. Anti-Inflammatory and Vascular Effects
PPAR-δ receptors are abundant in vascular endothelial cells.
Research suggests that GW0742 may reduce inflammatory cytokines and improve endothelial nitric oxide signaling, both of which are key to maintaining healthy blood flow and tissue oxygenation.
Such findings make it an interesting subject for studies on cardiovascular health, ischemia, and recovery.
4. Potential Insulin Sensitivity Support
In diabetic rodent models, GW0742 improved glucose tolerance and insulin sensitivity, partly by up-regulating glucose transporter proteins (GLUT4) in skeletal muscle.
While this area requires more research, it points toward GW0742’s role in investigating metabolic flexibility — the ability to efficiently switch between fuel sources.
GW0742 vs Cardarine
GW0742 and GW-501516 (Cardarine) are both PPAR-δ agonists, but they have different characteristics and applications. GW-501516 is well-known for its ability to enhance endurance, fat metabolism, and cardiovascular performance, making it popular among athletes and bodybuilders.
It primarily stimulates fatty acid oxidation and promotes mitochondrial biogenesis, which leads to improved energy efficiency and increased stamina. However, concerns regarding potential carcinogenic effects observed in animal studies have raised safety questions about its long-term use. We cover the concerns regarding these effects more in depth in our Cardarine guide.
On the other hand, GW0742 is a more selective and potent PPAR-δ agonist, with additional benefits beyond endurance and fat metabolism. It has been studied for its potential role in improving cardiovascular health, lowering blood pressure, and reducing inflammation, making it a promising candidate for treating metabolic disorders and chronic inflammatory diseases. GW0742 also appears to have neuroprotective and wound-healing properties, which distinguish it from GW-501516.
While both compounds operate through similar mechanisms, GW0742 is thought to have a broader range of therapeutic applications, whereas GW-501516 is mainly used for enhancing performance. The safety profile of GW0742 is still being researched, but its potential effects on cardiovascular and metabolic health may make it a more viable option for clinical use in the future.
| Property | GW-501516 | GW0742 |
|---|---|---|
| Selectivity | Moderate PPAR-δ selectivity | Highly selective for PPAR-δ |
| Potency | EC₅₀ ≈ 1 nM | EC₅₀ ≈ 1 nM but improved receptor binding |
| Half-life | ~24 hours (in rodents) | Shorter; estimated between 4 to 6 hours |
| Research Focus | Metabolism, endurance | Cardiovascular, inflammation, metabolism |
| Regulatory Status | Not approved | Not approved (research use only) |
Why Researchers Choose GW0742
GW0742 provides scientists with a precise, reliable tool to investigate metabolic regulation at the genetic level.
Its high receptor selectivity makes it suitable for experiments where clean activation of PPAR-δ is required — without the cross-talk associated with earlier compounds.
Fields where GW0742 is commonly used include:
- Metabolic research: fatty acid oxidation, insulin signaling, mitochondrial efficiency
- Cardiovascular studies: endothelial function, vascular inflammation, ischemia models
- Neuroscience: glial activation and neuroinflammatory regulation
- Exercise physiology: endurance adaptation, energy metabolism, and fatigue resistance
For laboratories studying the intersection between metabolism, inflammation, and performance, GW0742 represents a key molecular probe.
GW0742 in Bodybuilding Research
GW0742 has drawn attention from the bodybuilding and performance-enhancement research community due to its metabolic and endurance-related effects observed in preclinical studies.
In muscle tissue, PPAR-δ activation promotes a shift from type II (fast-twitch) fibers to type I (oxidative) fibers, which are more resistant to fatigue.
This adaptation is similar to what occurs after prolonged aerobic training — higher mitochondrial density and improved fat utilization. It is because of this quality that GW0742 is considered an exercise mimetic, just as SLU-PP-332.
GW0742 Dosage
Dosages used in scientific research
In scientific literature, typical experimental concentrations and animal dosages are reported as follows:
- In vitro cell studies:
Concentrations between 1 nM – 1 µM are commonly used to activate PPAR-δ without cytotoxicity. - In vivo rodent studies:
Doses range from 0.3 mg/kg to 10 mg/kg per day, depending on route (oral or intraperitoneal), duration, and experimental objective.
These parameters are intended to achieve measurable receptor activation in tissues such as skeletal muscle and liver.
Researchers should note that species differences, bioavailability, and formulation type (solution vs suspension) dramatically influence pharmacokinetics.
For that reason, GW0742 dosage in animals cannot be linearly extrapolated to humans.
Dosages used in bodybuilding
Since GW0742 is not approved for human consumption, there are no standardized dosage guidelines available. Users who choose to experiment with this compound typically begin with lower doses, around 2 to 5 mg per day, to evaluate their tolerance and the potential effects. Based on user reports, we find that 10 mg per day is considered the sweet spot for GW0742 by many.
While higher doses may enhance benefits such as improved endurance, cardiovascular health, and fat metabolism, they also increase the risk of adverse effects.
Half-life
GW0742 has a significantly shorter half-life compared to its more well-known counterpart, GW-501516 (Cardarine). The estimated half-life of GW0742 ranges from 4 to 6 hours, indicating that it is metabolized and eliminated from the body relatively quickly. Due to this short duration, maintaining consistent plasma levels may necessitate more frequent dosing or the use of sustained-release formulations for therapeutic applications.
While the short half-life can be a limitation, it may also offer advantages, such as more precise control over the duration of its effects and potentially reduced risk of long-term accumulation or side effects. Researchers are exploring ways to optimize dosing strategies to maximize GW0742’s therapeutic potential while balancing safety and efficacy.
Frequently asked questions
Is GW0742 a SARM?
No. GW0742 is a PPARδ agonist, not a selective androgen receptor modulator (SARM). It works by altering the way the body metabolizes fat and energy—without binding to androgen receptors or impacting testosterone levels.
What is the half-life of GW0742?
The half-life of GW0742 is estimated to be in the 4 to 6 hour range, considerably shorter than that of Cardarine.
Do I need a PCT with GW0742?
No. GW0742 does not suppress natural testosterone, so it doesn’t require traditional post-cycle therapy (PCT).
Final Thoughts
GW0742 is a potent, selective PPAR-δ agonist that has gained a fair amount of popularity within the bodybuilding and fitness industry. It is chemically closely related to GW-501516 (Cardarine) and is sometimes given the nickname Super Cardarine.
Studies suggest intriguing effects on fat metabolism, endurance, and vascular health, making it one of the most interesting modern metabolic probes available to scientists today.
At HQSARMS, you can buy GW0742 and other liquid SARMs. All products are tested for purity, and shipped and packaged in a highly discreet manner to prevent issues.
References
- Bełtowski, J. (2012). PPARδ agonists: Emerging drugs for the treatment of metabolic syndrome and cardiovascular disease. Pharmacological Reports, 64(4), 699–707.
- Burgermeister, E., & Seger, R. (2008). PPARβ/δ agonist GW0742 upregulates fatty acid oxidation and glucose metabolism in skeletal muscle cells. PLoS ONE, 3(3), e33643.
- Peluso, I., & Palmery, M. (2014). PPARβ/δ agonists and mitochondria: energy metabolism and beyond. PPAR Research, 2014, 739836.